HealthQuill Psoriatic Arthritis
Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over 50 years, has failed to meet its primary goal of being symptom-free after a year of therapy.
Drugs Health Pharma

Novartis’ drug to treat inflammation of arteries fails in end-stage trials

HQ Team July 3, 2025: Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over.

Read More
The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis.
Drugs Health Pharma

UK clears Janssen-Cilag’s drug for Crohn’s disease, ulcerative colitis

HQ Team May 19, 2025: The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease.

Read More